Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination

BACKGROUND: Immunity after SARS-CoV-2 infection or vaccination has been threatened by recently emerged SARS-CoV-2 variants. A systematic summary of the landscape of neutralizing antibodies against emerging variants is needed. METHODS: We systematically searched PubMed, Embase, Web of Science, and 3 pre-print servers for studies that evaluated neutralizing antibodies titers induced by previous infection or vaccination against SARS-CoV-2 variants and comprehensively collected individual data. We calculated lineage-specific GMTs across different study participants and types of neutralization assays. FINDINGS: We identified 56 studies, including 2,483 individuals and 8,590 neutralization tests, meeting the eligibility criteria. Compared with lineage B, we estimate a 1.5-fold (95% CI: 1.0–2.2) reduction in neutralization against the B.1.1.7, 8.7-fold (95% CI: 6.5–11.7) reduction against B.1.351 and 5.0-fold (95% CI: 4.0–6.2) reduction against P.1. The estimated neutralization reductions for B.1.351 compared to lineage B were 240.2-fold (95% CI: 124.0–465.6) reduction for non-replicating vector platform, 4.6-fold (95% CI: 4.0–5.2) reduction for RNA platform, and 1.6-fold (95% CI: 1.2–2.1) reduction for protein subunit platform. The neutralizing antibodies induced by administration of inactivated vaccines and mRNA vaccines against lineage P.1 were also remarkably reduced by an average of 5.9-fold (95% CI: 3.7–9.3) and 1.5-fold (95% CI: 1.2–1.9). INTERPRETATION: Our findings indicate that the antibody response established by natural infection or vaccination might be able to effectively neutralize B.1.1.7, but neutralizing titers against B.1.351 and P.1 suffered large reductions. Standardized protocols for neutralization assays, as well as updating immune-based prevention and treatment, are needed. FUNDING: Chinese National Science Fund for Distinguished Young Scholars